Drug Profile
KOS 1584
Alternative Names: 9,10-Didehydroepothilone D; KOS-1584; R 1645Latest Information Update: 21 Aug 2015
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Kosan Biosciences
- Class Antineoplastics; Epothilones
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 14 Apr 2008 Phase-II clinical trials in Non-small cell lung cancer in USA (IV)
- 30 Oct 2007 KOS 1584 is available for licensing worldwide (http://www.kosan.com)